Modality
Multispecific
MOA
TYK2i
Target
DLL3
Pathway
NF-κB
MyelofibrosisRettRSV
Development Pipeline
Preclinical
~May 2014
→ ~Aug 2015
Phase 1
~Nov 2015
→ ~Feb 2017
Phase 2
~May 2017
→ ~Aug 2018
Phase 3
Nov 2018
→ Aug 2031
Phase 3Current
NCT07841701
2,917 pts·Rett
2018-11→2025-01·Active
NCT06167390
1,046 pts·Rett
2022-12→2031-08·Active
NCT06863490
2,514 pts·Myelofibrosis
2024-10→TBD·Recruiting
6,477 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-01-241.2y agoPh3 Readout· Rett
2031-08-255.4y awayPh3 Readout· Rett
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Active
P3
Active
P3
Recruit…
Catalysts
Ph3 Readout
2025-01-24 · 1.2y ago
Rett
Ph3 Readout
2031-08-25 · 5.4y away
Rett
RecruitingActive|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07841701 | Phase 3 | Rett | Active | 2917 | OS |
| NCT06167390 | Phase 3 | Rett | Active | 1046 | BodyWt |
| NCT06863490 | Phase 3 | Myelofibrosis | Recruiting | 2514 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 |